Point of care test for non invasive differential diagnosis of obstrutive and non-obstructive azoospermia in male fertility

Objetivo

The project ANDROTEST aims at the development of a non-invasive point-of-care device for the differential diagnosis of
obstructive and non-obstructive azoospermia (medical condition of a man not having any measurable level of sperm in his
semen) in male infertility cases. Human infertility affects about 25% of couples. For many years, it was thought that infertility
was a “woman thing”. Nowadays it is well known that infertility is not such a woman thing, being estimated that in 40-50% of
infertility cases, the issue is on the man’s side. One of the most severe forms of male infertility is azoospermia, which is
characterized by an absence of sperm in the semen. Azoospermia is diagnosed in 20% of subfertile men and has two
forms: obstructive azoospermia (OA) and non-obstructive azoospermia (NOA). OA is caused by a physical obstruction in the
male reproductive tract. NOA is a more complicated infertility syndrome with the azoospermia being secondary to a failure to
produce sperm. For most men with azoospermia, testicular biopsy is currently the only method to definitively distinguish
between OA and NOA. Testicular biopsy is a surgical intervention procedure to remove a small sample of tissue from one or
both testicles for further examination under a microscope. The procedure has to be performed by a surgeon or an urologist
in an operating room and under local anaesthesia. It is therefore, an invasive procedure that implies significant costs for the
healthcare systems and that needs more than 2 weeks to deliver the results, because of the need for expert evaluation of
the sampled tissue. The invasiveness of the procedure, the elevated costs and the long times needed to deliver the results,
sustain the urgent need for an alternative non-invasive and faster approach with better diagnostic potential at lower costs.
This need is the one we have identified as a huge business opportunity we seek embracing.

Ámbito científico

medical and health sciencesclinical medicineandrology

Programa(s)

Tema(s)

PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Convocatoria de propuestas

H2020-SMEInst-2014-2015

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-SMEINST-1-2015

Régimen de financiación

SME-1 - SME instrument phase 1

Coordinador

TORO VENTURES FINANCIAL AND MANAGEMENT SERVICES SL

Aportación neta de la UEn

€ 50 000,00

Dirección

CALLE MIGUEL VILLANUEVA 2 6 PISO PUERTA 3
26001 LOGRONO
España

Pyme

Sí

Región

Noreste La Rioja La Rioja

Tipo de actividad

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Enlaces

Contactar con la organización

Participación en los programas de I+D de la UE

Red de colaboración de HORIZON

Coste total

€ 71 429,00